Importantly, TGF-β/Smad inhibitors have shown potential in alleviating the progression of renal fibrosis, highlighting the therapeutic potential of targeting this pathway in managing uremia [[102], [103], [104]]. This evidence concerns the gene TGFB1 and renal fibrosis.